Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal

A method of enhancing cognition or treating a disorder involving cognitive dysfunction in a mammal comprising administering to said mammal, an amount of

• a. a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof;
• and
• b. an acetylcholinesterase inhibitor, a butylcholinesterase inhibitor, an estrogenic agent, selective estrogen receptor modulator or muscarinic agonist or a pharmaceutically acceptable salt thereof;
• wherein the active ingredients (a) and (b) are administered in amounts that render the combination of the two ingredients effective in the treatment of diseases of cognitive dysfunction.

A method of treating a disorder or conditon selected from the group consisting of Alzheimer's Disease, mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease dementia, Huntington's Disease, Stroke, TBI, AIDS associated dementia and schizophrenia comprising adminstering to said mammal;

• (a) a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof;
• (b) an acetylcholinesterase inhibitor, a butylcholinesterase inhibitor, an estrogenic agent, a SERM, or a muscarnic agonist or a pharmaceutically acceptable salt thereof;
• and
• wherein the active agents (a) and (b) above are administered in amounts that render the combination of the two ingredients effective in treating Alzheimer's Disease, mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease dementia, Huntington's Disease, Stroke, TBI, AIDS associated dementia and schizophrenia.